Flipboard Science Desk"A unanimous panel of [U.S.] federal drug advisers on Monday concluded that Eli Lilly's experimental Alzheimer's drug donanemab benefits patients with early stages of the disease and that its benefits outweigh its risks."
@AxiosNews reports: https://flip.it/7_GWD0
#Alzheimers #Disease #EliLilly #Drugs #Pharmaceuticals #Medicine #Health #Aging
All ０７６萌ＳＮＳ content and data are available under the